Es Ghd Igfi Limitation

---
name: es-ghd-igfi-limitation
description: This skill determines whether serum insulin-like growth factor-1 (IGF-I) levels alone can be used to diagnose growth hormone deficiency (GHD) in childhood cancer survivors exposed to hypothalamic-pituitary axis radiotherapy. Triggers include questions such as “Can I rely on IGF-I alone to diagnose GHD after cranial radiation?” or “Is IGF-I sufficient for GHD assessment post-HP RT?”
---

# Evaluate IGF-I sufficiency for GHD diagnosis post-radiation

## STEP 1 — Gather Information
Collect radiation history (HP axis RT dose and timing), auxologic data (height velocity, height SDS, pubertal status), serum IGF-I level, and screen for other pituitary hormone deficiencies; compile data for next step.

## STEP 2 — Rule In / Rule Out
Is the serum IGF-I level below -2 SDS? If yes, proceed to evaluate need for confirmatory testing; if no, IGF-I alone insufficient to rule out GHD and further testing is required.

## STEP 3 — Classify or Stratify
Classify the case as “IGF-I insufficient for standalone GHD diagnosis” regardless of level, indicating need for provocative testing in HP axis RT-exposed survivors.

## STEP 4 — Decide
Do not rely solely on IGF-I; perform a validated provocative test (e.g., insulin tolerance test, glucagon, arginine, or GHRH-arginine) to establish GHD diagnosis.

## Clinical Guardrails / Mimics / Pitfalls
Do not use IGF-I alone to diagnose GHD after HP axis RT; avoid false reassurance from normal IGF-I levels; consider confounders such as malnutrition, obesity, hepatic disease, and active malignancy that can alter IGF-I independently of GH status.

## Concrete Clinical Example
A 14-year-old survivor of acute lymphoblastic leukemia who received 18 Gy cranial radiotherapy reports fatigue and decreased growth velocity; IGF-I is -1.0 SDS. Because IGF-I alone is insufficient, an insulin tolerance test is performed showing a peak GH of 2.5 µg/L, confirming GHD and prompting initiation of GH therapy.

**Source:** Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175